Zydus Lifesciences Secures USFDA Orphan Drug Status for Desidustat in Sickle Cell Disease

Zydus Lifesciences (

) announced on February 6, 2026, that the USFDA granted Orphan Drug Designation (ODD) to its oral therapy Desidustat for treating sickle cell disease (SCD), a rare condition impacting fewer than 200,000 US patients. Desidustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, aims to elevate hemoglobin levels and red blood cell counts, addressing key SCD pathologies. This status qualifies the drug for incentives like tax credits on clinical trials, waived user fees, and seven-year market exclusivity upon approval. A completed Phase II proof-of-concept trial demonstrated its potential efficacy and safety, with results pending peer-reviewed publication; prior studies explored anemia indications. Current SCD therapies, such as hydroxyurea and transfusions, face limitations including side effects and accessibility issues, highlighting Desidustat's prospective value. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.